Massachusetts
|
001-38787
|
83-1895370
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, no par value
|
CYCN
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
|
Item 8.01.
|
Other Events
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
Press Release dated March 18, 2021
|
Cyclerion Therapeutics, Inc.
|
|||
Dated: March 18, 2021
|
By:
|
/s/ Anjeza Gjino
|
|
Name:
|
Anjeza Gjino
|
||
Title:
|
Chief Financial Officer
|
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end